PALISADE BIO INC (PALI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.27+3.25%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PALI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 100.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
PALI — earnings in line
Dated 2026-08-10
of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Why it matters: Palisade reported $125.2 million in cash and said it could fund both planned readouts. Lower cash or a shorter runway could affect trial plans.
Worry ifA later filing reports cash below $100 million or says funds no longer cover the planned UC and Crohn’s Phase 2 readouts.
Less concerning ifA later filing says cash still covers both planned readouts, with no new funding need disclosed.
Why it matters: The filing is a key step toward testing PALI-2108 in Crohn’s disease. A late or missing filing would put the planned 2027 trial start at risk.
Supportive ifPalisade says it filed the ASCENTRA-CD IND by December 31, 2026.
Worry ifThe company reports that the IND submission moved past 2026 or has not been made by year-end.
Why it matters: Phase 1 results came from only five UC patients and five Crohn’s patients. New safety problems or weak response in Phase 2 would challenge those early signs.
Worry ifA Phase 2 update reports a serious safety issue linked to the drug, or a response below the study’s goal.
Less concerning ifA Phase 2 update reports no new serious safety issue linked to the drug, and a response at or above the study’s goal.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$297 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $889 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,000 loss on $10,000 · 60.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.